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Abstract: In chronic peritoneal dialysis (PD) therapy, peritoneal permeability is gradually enhanced over the duration of 
the therapeutic course, leading to a grave decline in the therapeutic efficiency. In recent years, a novel therapy (CD ther-
apy), which integrates PD therapy with hemodialysis therapy, is being applied to end-stage PD patients to complement the 
decline of therapeutic efficiency caused by the grave degeneration of the peritoneal tissue. To realize a harmonious intro-
duction of the CD therapy, this study developed a useful index (KAu/c), which evaluates both therapeutic efficiency and 
degeneration of peritoneal tissue. Using a mathematical model and KAu/c, we were able to validate the therapeutic effi-
ciency in the PD patients, and, in one case, propose a better prescription for the patient by employing the CD therapy. The 
clinical implementation of this methodology is indispensable with regard to expanding the therapeutic monitoring system 
for renal replacement therapy. 
Keywords: Peritoneal dialysis, Complementary dialysis, Diffusive selectivity index, Computer-aided diagnosis, Therapeutic 
monitoring. 
INTRODUCTION  
  Chronic peritoneal dialysis (PD) therapy is a well-known 
renal replacement therapy and has been widely used in the 
world in conjunction with chronic hemodialysis (HD) ther-
apy, as its clinical implementation provides support in many 
end-stage renal disease patients [1]. In chronic PD therapy, a 
slightly hyperosmotic washing solution called dialysate, is 
put into the peritoneal cavity of a patient using a peritoneal 
catheter, which is implanted into the abdominal cavity. The 
dialysate is exchanged four to five times a day by the patient. 
By employing the principles of osmotic flow, diffusive and 
convective transport, the metabolites and excess water in the 
body fluids are gradually removed to the dialysate. Com-
pared to patients on chronic HD therapy, residual renal func-
tion is better preserved in patients who are on chronic PD 
therapy [2,3]. Moreover, the dialysis outcome for the middle 
molecules is also superior for chronic PD therapy as com-
pared to that seen for chronic HD therapy [2,3]. 
  However, the peritoneal permeability gradually enhances 
with the course of therapeutic duration, which leads to a 
grave decline in both dialysis outcomes and excess water 
removal volume (therapeutic efficiency). Hence, it is ex-
tremely important to explore a better prescription for chronic 
PD therapy based on both the peritoneal permeability and the 
residual renal function. However, in most cases, patients are 
actually being treated without ever having any rigorous 
therapeutic monitoring of the peritoneal permeability.  
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  In recent years, a novel therapy (complementary dialysis 
therapy: CD therapy) that integrates PD therapy with HD 
therapy has been applied to end-stage PD patients as a way 
of preventing the decline of the therapeutic efficiency related 
to the grave degeneration of the peritoneal tissue [4]. In the 
CD therapy, the weekly regimen of patient is scheduled for 
one day of HD therapy after 5 or 6 days of PD therapy. Since 
the CD therapy combines PD therapy’s maintenance of body 
fluid homeostasis with the excellent therapeutic efficiency of 
the HD therapy, end-stage PD patients who show a decline 
in therapeutic efficiency caused by the grave degeneration of 
the peritoneal tissue exhibit improvements in both therapeu-
tic efficiency and quality of life when started on the CD 
therapy [5]. In addition, the CD therapy is particularly avail-
able for a transition between full time PD therapy and full 
time HD therapy, and makes it possible to alleviate the deg-
radation of peritoneal tissue by an effect of peritoneal rest 
produced by intermittent HD therapy [6,7]. The introduction 
of CD therapy is based on the dialysis outcomes of PD ther-
apy such as creatinine clearance (CCr) and Kt/V for urea. 
However, during PD therapy, artificial errors in clinical data 
such as drainage volume and residual abdominal dialysate 
volume can occur when patients exchange dialysate, which 
can greatly affect the reproducibility of the dialysis out-
comes. Furthermore, the multifarious therapeutic conditions 
that are available for PD therapy can also have an extreme 
influence on the dialysis outcomes, thus making it difficult to 
evaluate the degeneration of the peritoneal tissue by only 
using the dialysis outcomes. Therefore, development of a 
useful index that is capable of evaluating both dialysis out-
comes and the degeneration of the peritoneal tissue would be 
indispensable in being able to realize a harmonious introduc-
tion of CD therapy.  Computer-Aided Diagnostic System for CDT  The Open Biomedical Engineering Journal, 2008, Volume 2    11 
  A numerical analysis that employs a mathematical model 
for chronic PD therapy is one of the quantitative assessments 
for peritoneal permeability, and is useful for developing the 
indexes. Assuming that the peritoneum was homoporous, 
Popovich et al. constructed a mathematical model that were 
able to quantitatively estimate the mass transfers of both 
crystalloids and colloids during chronic PD therapy (Pyle-
Popovich’s model) [8]. In order to accurately represent the 
osmotic flow, Rippe et al. constructed a mathematical model 
based on a heteroporus theory (three-pore theory) [9]. 
Vonesh  et al. applied the concept of convective transport 
from the three-pore theory to the convective term of Pyle-
Popovich’s peritoneal dialysis model, thereby making it pos-
sible to estimate the dialysis outcomes for each of the pa-
tients (Vonesh’s model) [10]. By integrating Pyle-
Popovich’s model with the three-pore theory as well as in-
corporating Vonesh’s model, Hamada et al. were able to 
construct a mathematical model for chronic PD therapy that 
led to the development of intelligent software, which re-
sulted in better prescriptions for chronic PD therapy (Perito-
neal Dialysis Navigation: PD NAVI
®) [11-16]. In addition, 
the new software implemented a numerical simulator that 
can be used to estimate both the dialysis outcome and excess 
water removal volume of the CD therapy (Peritoneal and 
Hemo Dialysis Navigation: PHD NAVI
®) [17]. By using a 
simultaneous numerical optimization technique, these tools 
are able to determine a set of optimal kinetic parameters for 
each patient’s clinical condition, thereby supporting the re-
alization of an individualized therapy. Some of the parame-
ters are defined based on the morphological findings of the 
peritoneal tissue and are available for use in evaluating the 
peritoneal permeability. Therefore, products that employ 
these parameters are useful in the therapeutic monitoring of 
both the decline of dialysis outcomes and the enhancement 
of peritoneal permeability caused by the degeneration of 
peritoneal tissue, and have prospects of a useful index that 
assess an introduction of the CD treatment.  
  In the current paper, we propose a novel index employing 
kinetic parameters that evaluate both the dialysis outcomes 
and the peritoneal permeability, which allows for the verifi-
cation of an optimal introduction of the CD therapy. Then, 
by using the novel index, PD NAVI
® and PHD NAVI
® are 
integrated in order to increase the availability of a computer-
aided diagnostic system for harmonious introduction of 
complementary dialysis therapy. Moreover, the proposed 
system analyzes some clinical data for which the peritoneal 
permeability differs from patient to patient, and gives a bet-
ter prescription to a clinical case for which the novel index 
indicated an alert state. The clinical implementation of this 
methodology is an indispensable way to realize a suitable 
introduction of CD therapy and to develop a therapeutic 
monitoring system for chronic PD therapy.  
MATERIALS AND METHODS 
1. Kinetics for Chronic PD Therapy  
  A mathematical model that is capable of performing nu-
merical simulations of chronic PD therapy is now available 
for making diagnostic assessments such as the monitoring of 
peritoneal permeability and verifications of prescriptions 
[13-15]. In the current study, we developed a novel index 
that was able to evaluate both dialysis outcomes and the peri-
toneal permeability involving the degeneration of the perito-
neal tissue. To accurately evaluate membrane transport, this 
study adopted a precise model [16] for which the concept of 
convective transport from the three-pore theory [9] was ap-
plied to the convective term of Pyle-Popovich’s model [8]. 
The three-pore theory considers three kinds of pores, each 
with a different radius size on the capillary wall; i.e., Cell 
pore, Small pore and Large pore. Cell pore corresponds to 
the water channel (Aquaporin). When employing both diffu-
sive and convective transport, crystalloids and colloids are 
removed to the dialysate via the Small pore or Large pore, 
respectively. The equations for the models are as follows. 
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where the metabolite  X  of interest is denoted by the sub-
script X, corresponding to urea, creatinine, glucose, albumin 
and so forth. 
B V  and 
D V are the total body fluid volume and 
intraperitoneal dialysate volume (mL), respectively. 
B V im-
plies the space including the metabolite X of interest. 
B C  
and 
D C  are the well-mixed plasma and dialysate concentra-
tion (mg/mL), respectively. 
Lr C  is the residual renal clear-
ance (mL/min) and G  is the generation rate (mg/min). m   is 
the mass transfer rate for the peritoneal membrane (mg/min). 
KA is known as the overall mass transfer area coefficient 
(MTAC) (mL/min),   is the reflection coefficient (-), which 
can quantitatively evaluate the efficiency of the sieve for the 
convection transport, and C  is the mean metabolite concen-
tration found within the peritoneal membrane (mg/mL). 
UP Q  
is the osmotic flow rate of the Small or Large pores for 
transport of metabolite X of interest (mL/min). The net ul-
trafiltration volume and 
UP Q  were estimated by employing 
the three-pore theory, which was defined by the following 
equations.  
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where 
U Q  is the net ultrafiltration rate (mL/min), and 
UC Q , 
US Q  and 
UL Q  are the osmotic flow rates (mL/min) for the 
Cell pore, Small pore and Large pore, respectively.  Lymph  
is the lymphatic absorption rate (mL/min). 
C PS L , 
S PS L  
and 
L PS L are the hydraulic conductance (mL/min/mmHg) 
for the Cell pore, Small pore and Large pore, respectively, 
and  HP is the hydrostatic pressure (mmHg). 
S   and 
L   
are the reflection coefficient (-) for the Small pore and Large 
pore, respectively. Colloid osmotic pressure (mmHg) is rep-
resented by 
Onc  . The crystalloid osmotic pressures 
(mmHg) are 
Urea  , 
Crea  , etc., and are calculated using 
van’t Hoff’s equation. 
U V is the urine volume (mL). G , 
KA, 
C PS L , 
S PS L , 
L PS L ,  Lymph  and  HP are a set of 
unknown kinetic parameters, and need to be determined 
from the clinical data for each patient through the use of a 
simultaneous numerical optimization method [16]. This 
study numerically calculated a mathematical model, and es-
timated the time courses for both the concentration of me-
tabolites and the intraperitoneal dialysate volume [11-16]. 
2. Diffusive Selectivity Index 
  Some of the kinetic parameters for the chronic PD ther-
apy mathematical models are defined based on the features 
of the peritoneal tissue. Multiplying the overall mass transfer 
coefficient (K) by the peritoneal effective area (A) gives 
MTAC, which makes it possible to evaluate the peritoneal 
permeability based on the diffusive transport. For the chronic 
PD therapy, small solute removal is extremely dependent 
upon the diffusive transport in contrast to that required for 
the convective transport. Since peritoneal tissue degeneration 
affects the membrane transport, therapeutic monitoring of K 
for small solute makes it possible to observe the enhance-
ment of the peritoneal permeability caused by the degenera-
tion of the peritoneal tissue. Assuming the plasma concentra-
tions of the metabolites in the chronic PD patients are con-
stant within a single dialysate exchange, an approximated 
analytical solution for MTAC can be calculated based on 
equation (2) and as shown in following algebraic expression. 
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where  t  is the dwelling time (min),  () 0 D V  is the infusion 
volume, and  () 0 DX C  is the dialysate concentration of me-
tabolite immediately after infusion. n  implies a contribution 
of convective transport compared to diffusive transport, and 
is set equal to either 0.0, 0.5 or 1.0 [18-21]. In this study, n  
was set equal to 0.0 due to analyze the mass transfers of 
small solute such as urea and creatinine. Then, the approxi-
mated dialysis outcome for the small solute was calculated 
by employing equation (15), which was based on equation 
(14) [22].  
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where the left hand side of equation (15) corresponds to the 
clearance that evaluates the adequacy of the dialysis during 
the renal replacement therapy. Although equation (15) theo-
retically showed a relationship between the clearance and 
MTAC, it did not prove to be useful clinically due to the lack 
of normalization. As a result, this study defined the ratio 
(KAu/c) of the KA for urea to KA for creatinine, and as-
sessed the relationship between KAu/c and therapeutic effi-
ciency. 
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where  Kt  and CCr are urea clearance and creatinine clear-
ance, respectively. KAu/c implies a peritoneal diffusive se-
lectivity (Diffusive Selective Index), and is a dimensionless 
parameter which accurately evaluates a personal equation for 
the clinical data. The enhancement of peritoneal permeability 
based on the degeneration of peritoneal tissue increases the 
overall mass transfer coefficient (K) for both urea and 
creatinine and decreases a ratio of K for urea to that for 
creatinine. Therefore, KAu/c for High transporter is normally 
much larger than that for other transporters. As for the clear-
ances, the CANUSA study and the NKF-K/DOQI guidelines 
proposed clinical practice recommendations, which imply 
minimum requirements for the adequacy of dialysis on the 
chronic PD therapy [23-26]. The relationship between KAu/c 
and therapeutic efficiency was validated by applying the 
clinical practice recommendations to equation (16). 
3. Kinetics for HD Therapy 
  The Urea Kinetic Model [27] was applied to the HD 
therapy. The set of mass balance equations for the plasma 
concentration on the HD therapy was as follows. 
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where 
I V  and 
E V  are the intracellular fluid volume (mL) 
and the extracellular fluid volume (mL). 
I C  and 
E C  are the 
intracellular concentration (mg/mL) and the extracellular 
concentration (mg/mL). 
I G  and 
E G  are the intracellular 
generation rate (mg/min) and the extracellular generation 
rate (mg/min). 
C K  and 
LD C  are the clearance of the cellu-
lar membrane (mL/min) and clearance of the dialyzer mem-
brane (mL/min). 
I V , 
E V , 
I G , 
E G , 
C K  and 
LD C for each 
patient were determined by using empirical equations [17]. 
This study numerically calculated a mathematical model, and 
estimated the time courses for the concentration of the me-
tabolites [17]. Since 
LD C  is rather larger than 
C K , the time 
course for 
I C  showed a considerable discrepancy versus 
that seen for 
E C . Hence the total body fluid for the HD 
therapy was divided into two compartments: i.e., intracellu-
lar fluid and extracellular fluid. 
4. Kinetics for CD Therapy 
  The numerical simulations for the CD therapy were exe-
cuted by employing a set of mathematical models for both Computer-Aided Diagnostic System for CDT  The Open Biomedical Engineering Journal, 2008, Volume 2    13 
chronic PD and HD therapies. The dialysis outcomes for the 
CD therapy were estimated by employing weekly Clear 
Space (CS), which allows for the integration of the dialysis 
outcome for chronic PD therapy with that of HD therapy 
[17]. The CS, which divided quantity of solute removal by 
metabolite concentration in plasma, corresponds to the puri-
fied body fluid volume during the CD therapy. 
 However  CS was not normalized as a universal therapeu-
tic index, so that this study evaluated the dialysis outcome by 
employing the CS/VB, which cancels out individual differ-
ences between patients. The CS/VB was a dimensionless pa-
rameter, and may set the criterion that is common to all pa-
tients. Since the CS was quantitatively similar to the CCr 
implemented for PD, CS and CS/VB were evaluated based on 
the clinical practice recommendations for CCr and Kt/V for 
Urea on the chronic PD therapy [23-26]. The total amount of 
the fluid removal summed the weekly urine volume and the 
total ultrafiltration volume of CD therapy in a weekly regi-
men. In addition, the time course of the metabolite concen-
trations in plasma after having prescribed an arbitrary treat-
ment schedule was estimated by employing a set of mathe-
matical model for both the chronic PD and HD therapy. 
5. Peritoneal Function Test 
  In order to validate our methodology, three Japanese pa-
tients undergoing the chronic PD therapy underwent the peri-
toneal function tests shown in Fig. (1), leading to the accu-
mulation of sets of essential clinical data. There were multi-
ple dialysate samples collected, and these included two kinds 
of dialysate for which there were differing osmotic pressures 
i.e., a 360-mOsm/kg-solvent (Low-Sol’n) and a 400-
mOsm/kg-solvent (Mid-Sol’n). The essential clinical data 
collected for use in the unknown parameters optimization are 
shown in Table 1. The clinical tests that involved the PET 
[28] were scheduled so that there were three exchanges of 
Low-Sol’n and Mid-Sol’n, for which the dwelling times dif-
fered. The patient’s backgrounds are seen in Table 2. Since a 
management of total body fluid volume on CD therapy de-
pends on the chronic PD therapy, body surface area and total 
body fluid volume were estimated by employing the Gehan 
equation [29], and the Hume and Weyers equation [30], re-
spectively. These equations are available for kinetics for the 
chronic PD therapy [24-26]. All patients signed informed 
consents that allowed for the use of their clinical data in the 
studies that were conducted to validate the clinical effective-
ness of the proposed methodology.  
Table 1.  Measurement Data 
Dwell time  Inf. vol.  UF vol. 
Solute concentrations (Plasma, Dialysate and Urine) 
urea creatinine  glucose 
albumin Na  Cl 
Dwell time (min). 
Inf. vol.: Infusion volume (L). 
UF vol.: Ultrafiltration volume (L). 
 
Table 2.  Patients 
Age 50.3±6.4 
Male:Female  2 : 1 
BSA 1.71±0.16  m
2 
TBFV 36.0±6.5  L 
Urine 78.3±109.8  mL/day 
BSA: Body Surface Area [29]. 
TBFV: Total Body Fluid Volume [30]. 
 
RESULTS AND DISCUSSION 
  The accuracy of the mathematical model that were used 
to run a numerical simulation for chronic PD therapy was 
verified by using the clinical data acquired based on the peri-
toneal function test shown in Fig. (1). A simultaneous nu-
merical optimization technique for the PD NAVI
® deter-
mined a set of unknown kinetic parameters. The mass trans-
fer for the peritoneum was numerically estimated by apply-
ing the optimal kinetic parameters to a mathematical model 
for the chronic PD therapy. Fig. (2) showed a relationship 
between measured and calculated values of Kt/V for urea, 
CCr and drainage volume. The coefficients of determination 
for both Kt/V for urea and CCr were very high (R
2>0.92), 
which showed that calculated data were in good agreement 
with measured data. Therefore, the simultaneous numerical 
optimization technique on PD NAVI
® accurately determined 
a set of kinetic parameters related to mass transfer, and guar-
anteed an availability of analysis of the peritoneal permeabil-
ity employing KA for both urea and creatinine. On the other 
hand, the coefficient of determination for drainage volume 
(R
2>0.86) was lower than those for both Kt/V for urea and 
CCr. When patients exchange dialysate, clinical data such as 
drainage volume and residual abdominal dialysate volume 
can easily include unavoidable artificial errors involving a 
daily variance. Consequently, the calculated data of drainage 
volume showed a slight discrepancy with the measured data, 
which had an effect on the coefficient of determination for 
the drainage volume. As a result, the calculated data of 
drainage volume were in good agreement with the measured 
data, and a set of kinetic parameters related to hydraulic con-
ductance was also determined by employing the simultane-
 
 
 
 
 
 
 
 
 
Fig. (1). Timetable of the peritoneal function test. 
LS: low osmotic pressure solution; MS: middle osmotic pressure 
solution; BW: body weight; B1-B2: blood samples; VD1~ VD6: drain-
age; D1~ D6: drainage samples; VU: urine; U1: urine sample; PET: 
peritoneal equilibrium test [28]. Infusion volume of the dialysate is 
2.0 L. 
 
 
22:30 8:00 12:30 15:30 20:30 22:30 8:00
LS MS LS MS LS MS
VD1 VD2 VD3 VD4 VD6 VD5
D1 D2 D3 D4 D6 D5
B1 B2
VU U1 BW
PET
22:30 8:00 12:30 15:30 20:30 22:30 8:00
LS LS MS MS LS LS MS MS LS LS MS MS
VD1 VD2 VD3 VD4 VD6 VD5
D1 D2 D3 D4 D6 D5
B1 B2
VU U1 BW
PET
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ous numerical optimization technique on PD NAVI
®. Thus, 
as calculated by the PD NAVI
®, there was little discrepancy 
for both dialysis outcome and fluid removal volume as com-
pared to the measured data shown in Fig. (2). Since the nu-
merical simulation accurately estimated the dialysis outcome 
and fluid removal volume for the chronic PD therapy, the 
numerical analysis by PD NAVI
® can be used to validate the 
relationship between KAu/c and the therapeutic efficiency 
such as Kt/V for urea, CCr and drainage volume.  
  The dialysis outcome and fluid removal volume for each 
patient based on the prescriptions shown in Fig. (1) were 
compared with the clinical practice recommendations [24-
26] in order to determine the adequacy of the dialysis (Table 
3). Although the dialysis outcomes and fluid removal vol-
ume for both Patients 1 and 2 were sufficient to earn an ade-
quacy of dialysis designation, those for Patient 3 were equal 
to the clinical practice recommendations, which implies that 
a better prescription needs to be explored for this patient. 
Moreover, therapeutic efficiency for each patient was com-
pared using the KAu/c, which was determined by applying 
each patient’s clinical data to the PD NAVI
® (Table 3). With 
decreases of KAu/c there was an associated decrease in the 
dialysis outcomes, which qualitatively was in good agree-
ment with the peritoneal permeability properties that were 
based on the PET. KAu/c is a ratio of the  KA for urea to the 
KA for creatinine, and is a dimensionless parameter that 
does not involve the effective peritoneal area. Since the en-
hancement of the peritoneal permeability that is caused by 
the degeneration of the peritoneal tissue increases the overall 
mass transfer coefficient ( K ) and decreases the KAu/c, 
therapeutic monitoring of KAu/c makes it possible to observe 
both the enhancement of the peritoneal permeability and the 
degeneration of the peritoneal tissue. In addition, the KAu/c 
has the potential for use in meta-analyses on chronic PD 
therapy administered in multinational and multicenter stud-
ies, for which the clinical conditions differ from patient to 
patient. 
Table  3.  Relationship Between Adequacy of Dialysis and 
KAu/c 
   Pt1  Pt2  Pt3  CPR 
Kt/V  [-] 2.15  1.78  1.73  >1.70 
CCr  [L/1.73m
2] 61.6  60.4  54.2 >55.0 
FRV [L] 14.0  10.5  3.5  >  4.9 
KAu/c  [-] 2.21  1.80  1.39   
PET   Low  Ave  High   
Kt/V: Weekly Kt/V for urea. 
CCr: Weekly creatinine clearance. 
FRV: Weekly fluid removal volume. 
CPR: Clinical practice recommendations [24-26]. 
 
  The theoretical approach for chronic PD therapy that is 
based on an approximated analytical solution of a mathe-
matical model is useful for the elucidation of some of the 
properties of KAu/c. When KAu/c is defined as an independ-
ent variable in equation (16), one can numerically analyze a 
relationship between KAu/c and the therapeutic efficiencies. 
A s  s ee n  i n  F i g.  ( 3), the improvement of the dialysis out-
comes depended on increases of both KAu/c and the drainage 
volume. Moreover, the theoretical relationship is available 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Measured (actual) versus calculated values of dialysis 
outcome and drainage volume. 
These data correspond to the therapeutic efficiencies for a single 
exchange of dialysate. a) Kt/V for urea, b) CCr, c) drainage vol-
ume. The coefficients of determination for both Kt/V for urea and 
CCr were very high (R
2>0.92). Meanwhile, the coefficient of de-
termination for drainage volume (R
2>0.86) was lower than others. 
Since drainage volume can easily include unavoidable artificial 
errors, the calculated data showed a slight discrepancy with the 
measured data of drainage volume. As a result, the calculated data 
showed excellent agreement with the measured data, and a set of 
kinetic parameters was exactly determined by employing the si-
multaneous numerical optimization technique.  
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for verification of a feasibility of adequacy of dialysis based 
on each patient clinical data. In Fig. (3), both drainage vol-
ume and KAu/c for each patient in Table 3 were plotted on 
the relationship. Although both Patient 1 (low transporter) 
and Patient 2 (average transporter) achieved an adequacy for 
which the dialysis outcomes fully exceeded the minimum 
clinical practice recommendation (solid line), results for Pa-
tient 3 (high transporter) corresponded to the minimum clini-
cal practice recommendations, implying that a better pre-
scription for the patient needed to be pursued. These findings 
were in agreement with the results presented in Table 3. 
However, as noted in Fig. (3), in order to increase the Kt/V 
by 0.15, it would be necessary to increase the drainage vol-
ume by over 2.0 L per day in Patient 3. In addition, since the 
peritoneal permeability gradually enhances during the course 
of the therapeutic duration, maintaining high transporters 
such as Patient 3 on chronic PD therapy would be difficult at 
best to achieve. Thus, unfortunately, Fig. (3) implies that it is 
extremely difficult to determine better prescriptions for high 
transporters as compared to the other transporters. By em-
ploying a relationship shown in Fig. (3) for the purpose of 
the therapeutic monitoring of KAu/c, this makes it possible to 
easily evaluate the adequacy of the dialysis and in addition, 
provides useful findings on the therapeutic strategies. As for 
cases similar to the patient examined in this study, CD ther-
apy plays an important role in improving the dialysis out-
come and fluid removal volume. 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Verification of adequacy of dialysis using a theoretical 
relationship between drainage volume and KAu/c. 
When there were increases for both the drainage volume and KAu/c, 
dialysis outcome and fluid removal volume improved. Although 
both Patient 1 and Patient 2 achieved an adequacy of dialysis, Pa-
tient 3 corresponded to the minimum clinical practice recommenda-
tions [24-26]. Solid line is the curve for the minimum clinical prac-
tice recommendations. Patient 1, Patient 2 and Patient 3 correspond 
to the clinical data shown in Table 3. 
 
  The therapeutic efficiency for the CD therapy for Patient 
3 in Table 3 was estimated by applying the clinical data to 
the PHD NAVI
®. The treatment schedule for the PD pre-
scription for the CD therapy is shown in Fig. (1). Table 4 
shows the therapeutic condition for HD during the CD ther-
apy. In Table 5, the relationship between the weekly regimen 
and the therapeutic efficiency can be seen, with R1 sched-
uled for 7 days of PD, R2 scheduled for one day of HD and 
then a dialysis holiday after 5 days of PD, and R3 scheduled 
for one day of HD after 6 days of PD. In addition, the dialy-
sis outcomes were estimated by using CS [17]. Although 
dialysis outcomes for R2 increased more than those for R1, 
the fluid removal volume was below the clinical practice 
recommendations. However, the dialysis outcome and fluid 
removal volume for R3 completely met the clinical practice 
recommendations, which proved to be an effectual regimen 
for Patient 3. Thus, the CD therapy complements the decline 
of the therapeutic efficiency observed during chronic PD 
therapy by effectively employing the HD therapy, which is 
very useful in the realization of a long-term PD therapy. 
Moreover, numerical analyses that apply the PHD NAVI
® 
make it possible to easily explore better prescriptions and 
regimens for CD therapy with minimal nursing time. The 
monitoring of KAu/c by employing the relationship shown in 
Fig. (3) is indispensable for being able to realize a harmoni-
ous introduction of the CD therapy. The computer-aided 
diagnosis, which integrates the PD NAVI
® with KAu/c and 
PHD NAVI
®, is available for both the verification of ade-
quacy and the validation of the regimen for the chronic PD 
therapy that involves the CD therapy. When taken together, 
these may play an important role in the improvement of the 
quality of life for chronic PD patients. 
Table 4.  Therapeutic Conditions on HD Therapy 
Treatment time  240min 
Ultrafiltration rate  8.33mL/min 
Urea clearance  170mL/min 
Creatinine clearance  150mL/min 
 
Table 5.  Regimens and Therapeutic Efficiency on CD Ther-
apy 
   R1  R2  R3  CPR 
PD [day]  7 5 6   
HD [day]  0 1 1   
DH [day]  0 1 0   
CSu/VB  [-] 1.73  2.18  2.46  >1.70 
CSc  [L/1.73m
2] 54.2 75.2 86.3  >55.0 
FRV [L]  3.5  4.5  5.0  >4.9 
PD: Chronic peritoneal dialysis therapy. 
HD: Intermittent hemodialysis therapy. 
DH: Dialysis holiday. 
FRV: Weekly fluid removal volume. 
CSu/VB: Ratio of weekly CS for urea to total body fluid volume. 
CSc: Weekly CS for creatinine. 
CPR: Clinical practice recommendations [24-26]. 
 
CONCLUSIONS  
  A novel criterion (KAu/c), which evaluates the peritoneal 
permeability caused by the degeneration of the peritoneal 
tissue, was proposed by using a mathematical model for 
chronic PD therapy. Analysis of some of the clinical data, for 
which patient to patient peritoneal permeability differed, was 
performed in order to validate the clinical usefulness of 
KAu/c. The dialysis outcome and fluid removal volume de-
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creased with the decrease of KAu/c, which qualitatively was 
in good agreement with the properties of the peritoneal per-
meability that was based on PET. Moreover, the therapeutic 
monitoring of KAu/c made it possible to easily evaluate the 
adequacy of the dialysis and provided useful findings on 
potential therapeutic strategies. For one critical case, in 
which it proved difficult to keep the patient on the chronic 
PD therapy, we explored the possibilities for a better CD 
therapy prescription, and by using this method, we numeri-
cally demonstrated that the CD therapy complemented the 
decline of both the dialysis outcome and fluid removal vol-
ume that occurred for the chronic PD therapy by effectively 
employing the HD therapy. The computer-aided diagnosis 
which integrates PD NAVI
® with KAu/c and PHD NAVI
® is 
available for both verifying the adequacy and the validation 
of the regimen of chronic PD therapy that involves CD ther-
apy, and in the future may contribute to continued expansion 
of renal replacement therapies. 
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